PDF herunterladen
Zentralbl Chir 2024; 149(01): 96-115
DOI: 10.1055/a-2178-5907
Thoraxchirurgie – Positionspapier

Positionspapier zur Implementierung eines nationalen organisierten Programms in Deutschland zur Früherkennung von Lungenkrebs in Risikopopulationen mittels Low-Dose-CT-Screening inklusive Management von abklärungsbedürftigen Screening-Befunden

Statement Paper on the Implementation of a National Organized Program in Germany for the Early Detection of Lung Cancer in Risk Populations Using Low-dose CT Screening Including Management of Screening Findings
Hans Hoffmann   *
1   Sektion Thoraxchirurgie, Klinikum rechts der Isar, Technische Universität München, Deutschland
,
Rudolf Kaaks   *
2   Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
3   Translational Lung Research Center Heidelberg, Deutsches Zentrum für Lungenforschung, Deutschland
,
Stefan Andreas
4   Lungenfachklinik Immenhausen, Deutschland
5   Klinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Deutschland
6   Deutsches Zentrum für Lungenforschung, Gießen, Deutschland
,
Torsten T. Bauer
7   Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Jörg Barkhausen
8   Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Deutschland
,
Volker Harth
9   Zentralinstitut für Arbeitsmedizin und Maritime Medizin, Universitätsklinikum Hamburg-Eppendorf, Deutschland
,
Hans-Ulrich Kauczor
3   Translational Lung Research Center Heidelberg, Deutsches Zentrum für Lungenforschung, Deutschland
10   Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Heidelberg, Deutschland
,
Wulf Pankow
11   Taskforce Tabakentwöhnung, Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, Berlin, Deutschland
,
Katrin Welcker
12   Klinik für Thoraxchirurgie, Kliniken Maria Hilf GmbH, Akademisches Lehrkrankenhaus der RWTH Aachen, Mönchengladbach, Deutschland
,
Jens Vogel-Claussen   **
13   Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover, Deutschland
14   Biomedical Research in Endstage and Obstructive Lung Disease Hanover (BREATH), Deutsches Zentrum für Lungenforschung, Hannover, Deutschland
,
Torsten Gerriet Blum   **
7   Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
15   Medical School Berlin, Deutschland
,
Deutsche Röntgengesellschaft (Vorstand der Deutschen Röntgengesellschaft: Prof. Dr. med. Konstantin Nikolaou, Prof. Dr. med. Jörg Barkhausen, Prof. Dr. med. Christiane Kuhl, Dr. rer. nat. Frank Anton, Dr. med. Stefan Neuman, Prof. Dr. med. Arnd Dörfler, PD Dr. med. Friederike Körber, Prof. Dr. rer. medic. Martin Fiebich, Prof. Dr. med. Gerald Antoch, Dr. med. Kerstin Westphalen, Prof. Dr. Ulrike Attenberger, Prof. Dr. med. Frank Wacker, Prof. Dr. med. Johannes Weßling), Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (Vorstand der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin: Prof. Dr. med. Wolfram Windisch, Prof. Dr. med. Christian Taube, Prof. Dr. med. Torsten T. Bauer, Prof. Dr. med. Antje Prasse), Deutsche Gesellschaft für Thoraxchirurgie (Vorstand der Deutschen Gesellschaft für Thoraxchirurgie: Dr. med. Katrin Welcker, Dr. med. Ludger Hillejan, Prof. Dr. med. Hans-Stefan Hofmann, PD Dr. med. habil. Robert Scheubel, Dr. med. Erich Hecker, Prof. Dr. med. Corinna Ludwig, Prof. Dr. med. Thorsten Walles, Prof. Dr. med. Hauke Winter) › Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Der Prozess zur Implementierung der Lungenkrebsfrüherkennung mit Niedrigdosis-CT (LDCT) in Deutschland hat in den letzten Jahren deutlich an Dynamik gewonnen. Es wird erwartet, dass der von den Fachgesellschaften kommentierte Referentenentwurf des Bundesministeriums für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz (BMUV) zur Lungenkrebsfrüherkennung noch bis Ende 2023 in Kraft tritt. Basierend auf dieser Verordnung wird der Gemeinsame Bundesausschuss (G-BA) zeitnah ein Programm zur Lungenkrebsfrüherkennung mit LDCT aufsetzten. In diesem Positionspapier stellen die im Lungenkrebs-Screening beteiligten Fachgesellschaften erstmals konkrete Eckpunkte für ein einheitliches, strukturiertes und qualitätsgesichertes Früherkennungsprogramm für Lungenkrebs in Deutschland vor, um zu diesem Prozess konstruktiv beizutragen.

Abstract

The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process.

Schlüsselwörter

Lungenkrebs-Screening - Niedrigdosis-Computertomographie - Organisiertes Früherkennungsprogramm - Rundherd-Management

Key words

Lung Cancer Screening - Low-dose Computed Tomography - Organized Early Detection Program - Nodule Management

* geteilte Erstautorenschaft


** geteilte Letztautorenschaft


Supporting Information



Publikationsverlauf

Artikel online veröffentlicht:
10. Oktober 2023

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 International Agency for Research on Cancer, World Health Organization. Cancer Fact Sheets. 2022. Im Internet (Stand: 22.09.2023)
    PubMed
  • 2 Zentrum für Krebsregisterdaten, Robert Koch Institut. Lungenkrebs (Bronchialkarzinom). 2022. Im Internet (Stand: 22.09.2023)
    PubMed
  • 3 Luengo-Fernandez R, Leal J, Gray A. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-1174
    CrossrefPubMedSuche in Google Scholar
  • 4 Ellis J. The impact of lung cancer on patients and carers. Chron Respir Dis 2012; 9: 39-47
    CrossrefPubMedSuche in Google Scholar
  • 5 Bonney A, Malouf R, Marchal C. et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev 2022; (08) CD013829
    CrossrefPubMedSuche in Google Scholar
  • 6 Aberle DR, Adams AM, Berg CD. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
    CrossrefPubMedSuche in Google Scholar
  • 7 de Koning HJ, van der Aalst CM, de Jong PA. et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020; 382: 503-513
    CrossrefPubMedSuche in Google Scholar
  • 8 Field JK, Vulkan D, Davies MPA. et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur 2021; 10: 100179
    CrossrefPubMedSuche in Google Scholar
  • 9 Hunger T, Wanka-Pail E, Brix G. et al. Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021; 11: 1040
    CrossrefPubMedSuche in Google Scholar
  • 10 Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Langversion 2.1, Dezember 2022. AWMF-Registernummer: 020/007OL. Im Internet (Stand: 22.09.2023).
    PubMed
  • 11 Herth FJF, Reinmuth N, Wormanns D. et al. [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie 2019; 73: 573-577
    Thieme ConnectPubMedSuche in Google Scholar
  • 12 Kauczor HU, Baird AM, Blum TG. et al. ESR/ERS statement paper on lung cancer screening. Eur Radiol 2020; 30: 3277-3294
    CrossrefPubMedSuche in Google Scholar
  • 13 European Respiratory Society. Open letter – Increasing the early diagnosis of lung cancer in Europe: an essential milestone to tackle the biggest cancer killer. 2022. Im Internet (Stand: 22.09.2022).
    PubMed
  • 14 Institute for Quality and Efficiency in Health Care (IQWiG). Lung cancer screening with low-dose computed tomography. Extract of final report S19-02. Version 1.0, 19 October 2020. IQWiG Reports – Commission No. S19-02. Cologne, Germany. Im Internet (Stand: 22.09.2023).
    PubMed
  • 15 Bundesamt für Strahlenschutz (BfS). Bericht Lungenkrebsfrüherkennung mittels LDCT – Wissenschaftliche Bewertung des Bundesamtes für Strahlenschutz gemäß § 84 Absatz 3 Strahlenschutzgesetz. BfS-35/21. Im Internet (Stand: 22.09.2023).
    PubMed
  • 16 Bundesministerium für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz. Lungenkrebs-Früherkennungs-Verordnung (LuKrFrühErkV). Referentenentwurf einer Verordnung über die Zulässigkeit der Anwendung der Niedrigdosis-Computertomographie zur Früherkennung von Lungenkrebs bei Rauchern. 2023. Im Internet (Stand: 22.09.2023).
    PubMed
  • 17 Treskova M, Aumann I, Golpon H. et al. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. BMC Med 2017; 15: 162
    CrossrefPubMedSuche in Google Scholar
  • 18 Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung Cancer 2018; 124: 189-198
    CrossrefPubMedSuche in Google Scholar
  • 19 Pastorino U, Silva M, Sestini S. et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019; 30: 1162-1169
    CrossrefPubMedSuche in Google Scholar
  • 20 Doroudi M, Pinsky PF, Marcus PM. Lung Cancer Mortality in the Lung Screening Study Feasibility Trial. JNCI Cancer Spectr 2018; 2: pky042
    CrossrefPubMedSuche in Google Scholar
  • 21 Paci E, Puliti D, Lopes Pegna A. et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017; 72: 825-831
    CrossrefPubMedSuche in Google Scholar
  • 22 Wille MM, Dirksen A, Ashraf H. et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 2016; 193: 542-551
    CrossrefPubMedSuche in Google Scholar
  • 23 Infante M, Cavuto S, Lutman FR. et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 2015; 191: 1166-1175
    CrossrefPubMedSuche in Google Scholar
  • 24 Becker N, Motsch E, Trotter A. et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2020; 146: 1503-1513
    CrossrefPubMedSuche in Google Scholar
  • 25 Patz jr. EF, Pinsky P, Gatsonis C. et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-274
    CrossrefPubMedSuche in Google Scholar
  • 26 Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015; 24: 154-161
    CrossrefPubMedSuche in Google Scholar
  • 27 Gonzalez Maldonado S, Motsch E, Trotter A. et al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial. Int J Cancer 2021; 148: 1097-1105
    CrossrefPubMedSuche in Google Scholar
  • 28 Meza R, Jeon J, Toumazis I. et al. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 2021; 325: 988-997
    CrossrefPubMedSuche in Google Scholar
  • 29 Li M, Zhang L, Charvat H. et al. The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials. Int J Cancer 2022; 151: 1491-1501
    CrossrefPubMedSuche in Google Scholar
  • 30 Rampinelli C, De Marco P, Origgi D. et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ 2017; 356: j347
    CrossrefPubMedSuche in Google Scholar
  • 31 Nekolla EA, Brix G, Griebel J. Lung Cancer Screening with Low-Dose CT: Radiation Risk and Benefit-Risk Assessment for Different Screening Scenarios. Diagnostics (Basel) 2022; 12: 364
    CrossrefPubMedSuche in Google Scholar
  • 32 Brain K, Lifford KJ, Carter B. et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. Thorax 2016; 71: 996-1005
    CrossrefPubMedSuche in Google Scholar
  • 33 Rasmussen JF, Siersma V, Pedersen JH. et al. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer 2015; 87: 65-72
    CrossrefPubMedSuche in Google Scholar
  • 34 van den Bergh KA, Essink-Bot ML, Borsboom GJ. et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011; 38: 154-161
    CrossrefPubMedSuche in Google Scholar
  • 35 van den Bergh KA, Essink-Bot ML, Borsboom GJ. et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010; 102: 27-34
    CrossrefPubMedSuche in Google Scholar
  • 36 Gareen IF, Duan F, Greco EM. et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer 2014; 120: 3401-3409
    CrossrefPubMedSuche in Google Scholar
  • 37 Williamson S, Patterson J, Crosby R. et al. Communication of cancer screening results by letter, telephone or in person: A mixed methods systematic review of the effect on attendee anxiety, understanding and preferences. Prev Med Rep 2019; 13: 189-195
    CrossrefPubMedSuche in Google Scholar
  • 38 Jonas DE, Reuland DS, Reddy SM. et al. Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 198. AHRQ Publication No. 20 – 05266-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2021. Im Internet (Stand: 22.09.2023)
    Suche in Google Scholar
  • 39 Kaaks R, Delorme S. Lung Cancer Screening by Low-Dose Computed Tomography – Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting. Rofo 2021; 193: 527-536
    Thieme ConnectPubMedSuche in Google Scholar
  • 40 Knoke JD, Shanks TG, Vaughn JW. et al. Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: an analysis of CPS-I data. Cancer Epidemiol Biomarkers Prev 2004; 13: 949-957
    CrossrefPubMedSuche in Google Scholar
  • 41 Vlaanderen J, Portengen L, Schuz J. et al. Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY Study. Am J Epidemiol 2014; 179: 290-298
    CrossrefPubMedSuche in Google Scholar
  • 42 Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160: 330-338
    CrossrefPubMedSuche in Google Scholar
  • 43 Krist AH, Davidson KW, Mangione CM. et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325: 962-970
    CrossrefPubMedSuche in Google Scholar
  • 44 Hüsing A, Kaaks R. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data. Eur J Epidemiol 2020; 35: 899-912
    CrossrefPubMedSuche in Google Scholar
  • 45 Behr CM, Oude Wolcherink MJ, IJzerman MJ. et al. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. Pharmacoeconomics 2023; 41: 395-411
    CrossrefPubMedSuche in Google Scholar
  • 46 Toumazis I, de Nijs K, Cao P. et al. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 2021; 7: 1833-1842
    CrossrefPubMedSuche in Google Scholar
  • 47 Ten Haaf K, Tammemägi MC, Bondy SJ. et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med 2017; 14: e1002225
    CrossrefPubMedSuche in Google Scholar
  • 48 UK National Screening Committee. UK NSC screening recommendation: Adult screening programme – Lung cancer. 2022. Im Internet (Stand: 22.09.2023).
    PubMed
  • 49 Morgan H, Baldwin DR. Important parameters for cost-effective implementation of lung cancer screening. Br J Radiol 2023; 96: 20220489
    CrossrefPubMedSuche in Google Scholar
  • 50 Balata H, Ruparel M, OʼDowd E. et al. Analysis of the baseline performance of five UK lung cancer screening programmes. Lung Cancer 2021; 161: 136-140
    CrossrefPubMedSuche in Google Scholar
  • 51 Vogel-Claussen J, Lasch F, Bollmann BA. et al. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography. Rofo 2022; 194: 1333-1345
    Thieme ConnectPubMedSuche in Google Scholar
  • 52 Duell M, Wiethege T. Das erweiterte Vorsorgeangebot (EVA) zur Lungenkrebsfrüherkennung – Update 2019. DGUV Forum 2020; 15-17
    PubMedSuche in Google Scholar
  • 53 Blum TG, Morgan RL, Durieux V. et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J 2023; 61: 2103201
    CrossrefPubMedSuche in Google Scholar
  • 54 Deutsche Krebsgesellschaft (DKG). OncoMap – Liste der zertifizierten Krebszentren. 2023. Im Internet (Stand: 22.09.2023).
    PubMed
  • 55 Deutsche Krebsgesellschaft (DKG). Jahresbericht der zertifizierten Lungenkrebszentren. Kennzahlenauswertung 2022. Auditjahr 2021/Kennzahlenjahr 2020. Im Internet (Stand: 22.09.2023).
    PubMed
  • 56 American College of Radiology Committee on Lung-RADS. Lung-RADS Assessment Categories 2022. Im Internet (Stand: 22.09.2023)
    PubMed
  • 57 Oudkerk M, Devaraj A, Vliegenthart R. et al. European position statement on lung cancer screening. Lancet Oncol 2017; 18: e754-e766
    CrossrefPubMedSuche in Google Scholar
  • 58 Tanner NT, Kanodra NM, Gebregziabher M. et al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 2016; 193: 534-541
    CrossrefPubMedSuche in Google Scholar
  • 59 Crosbie PA, Balata H, Evison M. et al. Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. Thorax 2019; 74: 405-409
    CrossrefPubMedSuche in Google Scholar
  • 60 Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012; 157: 571-573
    CrossrefPubMedSuche in Google Scholar
  • 61 International Association for the Study of Lung Cancer (IASLC). United Kingdom-Based Smoking Cessation Program Reports That 30 Percent of Support in a Lung Cancer Screening Program: The Yorkshire Enhanced Stop Smoking Study (YESS). 2022. Im Internet (Stand: 22.09.2023).
    PubMed
  • 62 Evans WK, Gauvreau CL, Flanagan WM. et al. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. CMAJ Open 2020; 8: E585-E592
    CrossrefPubMedSuche in Google Scholar
  • 63 Fucito LM, Czabafy S, Hendricks PS. et al. Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Cancer 2016; 122: 1150-1159
    CrossrefPubMedSuche in Google Scholar
  • 64 American Lung Association. Smoking Cessation Interventions and Lung Cancer Screening. 2019. Im Internet (Stand: 22.09.2023).
    PubMed
  • 65 Herth FJF, Reinmuth N, Wormanns D. et al. [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie 2019; 73: 573-577
    Thieme ConnectPubMedSuche in Google Scholar
  • 66 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. AWMF-Register Nr. 076-006. 2021. Im Internet (Stand: 22.09.2023).
    PubMed
  • 67 Rabenstein A, Aydin D, Lochbühler K. [Smoking cessation interventions in clinical practice]. MMW Fortschr Med 2021; 163: 32-34
    CrossrefPubMedSuche in Google Scholar
  • 68 Ministry of Health New Zealand. The New Zealand Guidelines for Helping People to Stop Smoking. 2021. Im Internet (Stand: 22.09.2023).
    PubMed
  • 69 Kastaun S, Viechtbauer W, Leve V. et al. Quit attempts and tobacco abstinence in primary care patients: follow-up of a pragmatic, two-arm cluster randomised controlled trial on brief stop-smoking advice – ABC versus 5 As. ERJ Open Res 2021; 7: 00224-2021
    CrossrefPubMedSuche in Google Scholar